

Update on biomarkers in neuromyelitis optica

OPEN

Esther Melamed, MD,
PhD
Michael Levy, MD, PhD
Patrick J. Waters, PhD
Douglas Kazutoshi Sato,
MD, PhD
Jeffrey L. Bennett, MD,
PhD
Gareth R. John, PhD
Douglas C. Hooper, PhD
Albert Saiz, MD
Amit Bar-Or, MD, PhD
Ho Jin Kim, MD
Lakha Pandit, MD
Maria Isabel Leite, MD,
DPhil
Nasrin Asgari, MD, PhD
Najib Kissani, MD
Rogier Hintzen, MD,
PhD
Romain Marignier, MD
Sven Jarius, MD
John Marcelletti, PhD
Terry J. Smith, MD
Michael R. Yeaman, PhD
May H. Han, MD
On behalf of the GJCF-
ICC&BR

Correspondence to
Dr. Han:
mayhan@stanford.edu

Supplemental data
at Neurology.org/nn

ABSTRACT

Neuromyelitis optica (NMO) (and NMO spectrum disorder) is an autoimmune inflammatory disease of the CNS primarily affecting spinal cord and optic nerves. Reliable and sensitive biomarkers for onset, relapse, and progression in NMO are urgently needed because of the heterogeneous clinical presentation, severity of neurologic disability following relapses, and variability of therapeutic response. Detecting aquaporin-4 (AQP4) antibodies (AQP4-IgG or NMO-IgG) in serum supports the diagnosis of seropositive NMO. However, whether AQP4-IgG levels correlate with disease activity, severity, response to therapy, or long-term outcomes is unclear. Moreover, biomarkers for patients with seronegative NMO have yet to be defined and validated. Collaborative international studies hold great promise for establishing and validating biomarkers that are useful in therapeutic trials and clinical management. In this review, we discuss known and potential biomarkers for NMO. *Neurol Neuroimmunol Neuroinflamm* 2015;2:e134; doi: 10.1212/NXI.000000000000134

GLOSSARY

AQP4 = aquaporin-4; **BAFF** = B-cell activating factor; **BBB** = blood-brain barrier; **CBA** = cell-based assay; **GFAP** = glial fibrillary acidic protein; **ICAM-1** = intercellular adhesion molecule-1; **IFN** = interferon; **IL** = interleukin; **MMP-9** = matrix metalloproteinase-9; **MOG** = myelin oligodendrocyte glycoprotein; **MS** = multiple sclerosis; **NF** = neurofilament; **NMO** = neuromyelitis optica; **NMOSD** = NMO spectrum disorder; **ON** = optic neuritis; **OSMS** = opticospinal MS; **T_H** = T helper cell; **VCAM-1** = vascular cell adhesion molecule-1; **VEGF-A** = vascular endothelial growth factor-A.

Neuromyelitis optica (NMO) (and NMO spectrum disorder [NMOSD]) is an inflammatory autoimmune disease of the CNS.¹ It was first described in the 19th century by Gault and Devic, among others.² NMO usually presents with acute or repeated episodes of optic neuritis (ON) and longitudinal transverse myelitis.³ It presents less commonly as a unique area postrema syndrome accompanied by intractable vomiting and hiccups.⁴ NMO/NMOSD may be monophasic; however, the frequency of truly monophasic disease is difficult to estimate, as interval attacks may last several years.^{5,6} The incidence of NMO is highest during the third to fourth decade of life, with a considerably higher frequency among females (female-to-male ratio as high as 9–10:1).⁷

Detection of complement-fixing antibodies directed against aquaporin-4 (AQP4; also known as AQP4-IgG or NMO-IgG) in the majority of patients with the NMO clinical syndrome has highlighted NMO/NMOSD as a distinct disease entity from multiple sclerosis (MS).^{8,9} Extensive research has now established significant differences in the clinical, immunologic, histopathologic, and imaging characteristics between NMO/NMOSD and MS.^{10–12}

From Stanford University (E.M., M.H.H.), Stanford, CA; Johns Hopkins University (M.L.), Baltimore, MD; University of Oxford (P.J.W.), UK; Tohoku University (D.K.S.), Sendai, Japan; University of São Paulo (D.K.S.), Brazil; University of Colorado (J.L.B.), Denver; Mt. Sinai University (G.R.J.), New York, NY; Thomas Jefferson University (D.C.H.), Philadelphia, PA; IDIBAPS (A.S.), Barcelona, Spain; Montreal Neurological Institute and Hospital (A.B.-O.), McGill University, Montreal, Quebec, Canada; Research Institute and Hospital of National Cancer Center (H.J.K.), Goyang, Korea; KS Hegde Medical Academy (L.P.), Nitte University, Mangalore, India; Oxford University Hospital (M.L.L.), Oxford, UK; University of Southern Denmark (N.A.), Odense; Vejle Hospital (N.A.), Denmark; University Hospital (N.K.), Marrakech, Morocco; MS Center (R.H.), Erasmus MC University Medical Center, Rotterdam, the Netherlands; Service de Neurologie A (R.M.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, France; Molecular Neuroimmunology (S.J.), Department of Neurology, University Hospital Heidelberg, Germany; Tandem Labs (J.M.), San Diego, CA; University of Michigan Medical School (T.J.S.), Ann Arbor, MI; and David Geffen School of Medicine (M.R.Y.), University of California, Los Angeles.

GJCF-ICC&BR coinvestigators are listed at Neurology.org/nn.

Funding information and disclosures are provided at the end of the article. Go to Neurology.org/nn for full disclosure forms. The Article Processing Charge was paid by Guthy-Jackson Charitable Foundation.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Presence of AQP4-IgG has also facilitated the diagnosis and early treatment of patients with NMO/NMOSD. However, studies correlating serum AQP4-IgG titers with disease activity, severity, outcome, and response to therapy have yielded inconsistent results.¹³⁻¹⁵ The search for additional biomarker candidates in NMO has resulted in several interesting leads, though they remain to be further validated.^{16,17} In this article, we will review the current landscape of biomarker(s)/biomarker candidates in NMO and NMOSD, consider their clinical implications, and propose potential analytic platforms for future NMO biomarker discovery, validation, and application.

DESIGN OF LITERATURE REVIEW Along with manual literature review by authors with expertise in the field, published peer-reviewed articles were

interrogated to assess the current knowledge about biomarkers in NMO/NMOSD. A search of the PubMed database (National Center for Biotechnology Information, US National Library of Medicine) was performed using the query terms “biomarker,” “NMO,” “opticospinal multiple sclerosis (OSMS),” “blood,” “serum,” and “CSF.” NMO and NMOSD met the criteria proposed by Wingerchuk et al.¹⁸ The analysis included published literature up to 2014. Although it was not possible to cite every published report in this review, all of the meritorious efforts to discover and validate potential biomarkers in NMO/NMOSD are appreciated. Every effort was made to highlight universally accepted themes. See the figure for a summary of biomarker candidates in NMO and MS and their current evidence levels.

I. AQP4-IgG AND OTHER SEROLOGIC MARKERS
AQP4-IgG/NMO-IgG. AQP4-IgG was the first proposed biomarker of NMO/NMOSD and has become a sine qua non of NMO diagnosis. Given

Figure Summary of relative biomarkers candidate levels in CSF and sera of NMO and MS patients

Fluid Phase BC	CSF			Sera		
	NMO	MS	OSMS	NMO	MS	OSMS
IL-1alpha					↔	
IL-1beta	↑	↑		↑	↑	
IL-1Ra	↑	↑			↑	
IL-1RII					↑	
IL-2	↔				↔	
IL-2R					↔	
IL-3						
IL-4	↔	↔			↓	
IL-5	↔	↔		↑	↔	
IL-6	↑	↔		↑	↔	
sIL-6R		↔			↔	
IL-7	↓	↓				
IL-8/CXCL8	↑	↑		↑	↑	
IL-9	↔	↔				
IL-10	↑	↑			↑	
IL-11						
IL-12p40	↔	↑			↔	
IL-12p70		↑			↔	
IL-13	↑	↑			↑	
IL-14						
IL-15	↔	↔				
IL-16						
IL-17	↑	↑	↑	↑	↑	↑
IL-18		↑			↑	
IL-19-IL-20						
IL-21	↑			↑		
IL-22						
IL-23				↑	↑	
IL-24-IL-35						
APRIL		↔		↑	↔	
BAFF	↑	↑		↑		
sICAM-1						
CXCL8						
NF				↑		
BLC						
CXCL10 (IP-10)						
Haptoglobin	↑					

Fluid Phase BC	CSF			Sera		
	NMO	MS	OSMS	NMO	MS	OSMS
IFNγ	↔	↑			↑	↑
G-CSF	↑	↔				
GM-CSF	↔	↑			↑	
TNF-alpha	↑	↑			↔	
CCL2/MCP-1	↓	↓				
CCL3/MIP-1alpha	↑					
CCL4/MIP1beta	↔	↔				
CCL5/RANTES	↔	↑			↑	
CCL9		↑			↔	
CXCL10/IP-10	↑	↑		↑	↔	
CCL11/Eotaxin	↑	↔			↔	
CCL17/TARC		↔			↓	
CCL22		↑			↔	
PDGF-GG	↑	↔				
VEGF	↔	↔			↑	
TGF Beta		↑			↔	
bGFG	↑	↔				
ECP	↑	↔		↔	↔	
Eotaxin-2	↑	↔		↔	↔	
Eotaxin-3	↑	↔		↔	↔	
sCD26	↔	↔		↔	↔	
sCD30	↔	↑		↔	↔	
MMP-8	↑				↑	
MMP-9	↑			↑	↔	
TIMP1					↔	
C4b				↑	↔	
FBb				↑	↔	
SC5b-C9				↑	↔	
GFAP	↑	↔		↔	↔	
S100B	↑	↔		↑		
MBP	↑	↑				
HMGB1						
chitinase	↑					
CXCL8			↑			
CXCL13						
ICAM	↑			↑		
VCAM	↑					

its high specificity, NMO-IgG was added as a supportive criterion in the revised 2006 NMO diagnostic criteria.¹⁸ To date, AQP4 is the main clinically approved biomarker for NMO. AQP4, the most abundant water channel in the CNS, is found predominantly on astrocyte foot processes forming the glia limitans of the blood-brain barrier (BBB) and around synapses at nodes of Ranvier.¹⁹ The AQP4 protein is highly expressed in the brainstem, hypothalamus, diencephalon, spinal cord, and optic nerves, correlating with the frequent distribution of NMO lesions.²⁰ AQP4 is also found in kidney, stomach, placenta, and more isolated regions of the CNS (such as granular layer of the cerebellum, hippocampus, and globus pallidus), but most of these tissues are not known to be involved in NMO/NMOSD.^{21,22} Extensive experimental evidence supports an important contribution of AQP4-IgG to disease pathogenesis.^{23–26} It is evident that NMO-IgG from the systemic circulation enters the CNS through a disrupted BBB; however, it is also possible that anti-AQP4 is generated intrathecally.^{24,25,27} The latter scenario has implications for potential detection of AQP4-IgG in CSF vs serum. AQP4-IgG (primarily IgG1 subclass) binds avidly to AQP4, resulting in complement fixation, generation of chemotactic signals (e.g., C3a, C5a), immune cell infiltration, and subsequent loss of AQP4 and glial fibrillary acidic protein (GFAP) in astrocytes.^{28–31}

Detection of AQP4-IgG has improved over the past decade. First-generation tissue-based immunofluorescence assays had relatively low sensitivity (48%–54% for a single assay or 72% in a combination assay using recombinant human AQP4 ELISA and transfected cell-based assays [CBAs]) and specificity of up to 100%.^{32–34} Newer techniques, such as optimized immunohistochemistry assay, can detect AQP4-IgG with 74.8% sensitivity and 100% specificity.³⁵ Antibody directed against the M23 isoform of AQP4 in orthogonal arrays has been reported to have the highest sensitivity for the diagnosis of NMO/NMOSD.³⁶ Live CBAs, particularly those using the M1-AQP4 isoform as antigen, have had the lowest false-positive rates.³⁷ The importance of assay methodology for the differential diagnosis of NMO vs MS has recently been underscored by the findings of Pittock et al.,³⁸ suggesting caution in interpretation of results obtained using ELISA.

AQP4-IgG assessment can be helpful with disease monitoring in certain cases. AQP4-IgG is found in 74% of recurrent NMO cases,³⁹ and initial seropositivity correlates with higher relapse rates than seronegative status.⁹ Of interest, AQP4-IgG can predate clinical symptoms by up to 10 years.⁴⁰ Patients with NMO often benefit from plasmapheresis, presumably due to reduction in circulating AQP4-IgG and/or

other circulating soluble factor(s).^{41,42} However, the utility of monitoring AQP4-IgG titers during a distinct clinical relapse is less clear. AQP4-IgG titers also may not predict extent of spinal disease.^{14,43} Immunosuppressive therapies (such as azathioprine, cyclophosphamide, or rituximab) can lower AQP4-IgG titers during remission; however, disease quiescence can occur with persistently high NMO-IgG titers.⁴⁴ Currently, NMO-IgG titers do not appear to be a reliable indicator of disease activity or prognosis. Larger longitudinal studies will establish criteria for and usefulness of serial NMO-IgG testing.

Despite the clinical utility of AQP4-IgG in NMO diagnosis, several caveats preclude its use as a universal NMO biomarker. Approximately 20%–30% of patients with the clinical syndrome of NMO lack detectable AQP4-IgG, while in older studies up to 5%–10% of patients with MS were AQP4-IgG positive; however, seronegative cases have significantly decreased with the use of newer CBAs.^{9,45} AQP4-IgG seropositivity also varies widely based on geographic location and ethnicity. Among Caucasians, 56%–73% of patients with NMO/NMOSD are AQP4-IgG positive,^{9,46,47} whereas 33.3% of Caribbean patients, 47% of Italian patients, 63%–90% of Japanese patients, and 70%–76.9% of Chinese patients are seropositive.^{48–51} The wide variability in serostatus may reflect multiple factors, including ethnicity, sex, age, disease activity, immune therapies, and variations in assay techniques.⁵² Collectively, the complexities associated with use of AQP4-IgG as a standard biomarker in NMO/NMOSD emphasize the importance of optimization and standardization of assays and clinical diagnostic criteria.

Anti-MOG and other autoantibodies in AQP4-IgG-seronegative cases.

Recently, additional autoantibodies have gained attention as candidate biomarkers of NMO/NMOSD, particularly in seronegative cases. Antibodies against myelin oligodendrocyte glycoprotein (MOG-IgG) have been observed in 20%–40% of pediatric patients with acute disseminated encephalomyelitis, ON, and relapsing demyelination disorders, including NMO/NMOSD.^{53–55} MOG localizes to the outer surface of oligodendrocytes and the myelin sheath.⁵⁶ Mader et al.⁵⁷ first reported anti-MOG-IgG in a proportion of AQP4-IgG-seronegative adult and pediatric patients with NMO/NMOSD. Most recently, Ramanathan et al.⁵⁸ found a strong association between anti-MOG antibodies and bilateral relapsing ON in AQP4-IgG-seronegative patients (sensitivity 69%, specificity 99% in their retrospective adult patient cohort). In their study, MOG-IgG-seropositive patients tended to be younger females with a preceding infection and a relapsing course. Monophasic nature in anti-MOG-seropositive cases

has also been reported.^{59,60} Currently, the exclusive expression of AQP4-IgG or MOG-IgG in individual patients with NMO is suggested; however, improved assay conditions in larger randomized cohorts are needed to shed light on MOG-IgG's utility as a biomarker in AQP4-IgG-negative NMO/NMOSD cases and the relationship between these 2 biomarkers.

Other reported autoantibodies in NMO/NMOSD include NMDA-type glutamate receptor (e.g., CV2/CRMP5) and glycine receptor antibodies.^{e1-e4} Antibodies against other aquaporin proteins (e.g., AQP1) also appear to be promising.^{e5} Autoantibody panels (e.g., presence of anti-acetylcholine receptor, anti-thyroid, and anti-nuclear antibodies) may be important in understanding the connection between NMO/NMOSD and coexisting autoimmune diseases such as myasthenia gravis, autoimmune thyroid disorders, and lupus.^{e6}

II. B CELLS B cell dysregulation appears to be at the core of NMO/NMOSD pathogenesis. For instance, B cells expressing anti-AQP4 antibodies in the CSF and elevated levels of circulating plasmablasts are found in patients with acutely active NMO.^{17,23,e7} Specific B cell subsets have been implicated as potential biomarker candidates during relapses in patients with NMO. For example, CD138⁺HLA-DR⁺ plasmablasts are more abundant in the peripheral blood of patients with NMO and are enriched in the fraction of CSF lymphocytes during a relapse.^{e7} From a therapeutic standpoint, efficacy of an anti-CD20 monoclonal antibody (rituximab) may be related to the magnitude of B cell depletion and the repopulation of memory B cells.^{e8} Interleukin (IL)-6 signaling plays an important role in antibody-producing plasmablast survival and has an impact on the germinal center maturation of memory B cells in NMO.¹⁷ Alternatively, inhibition of IL-6 signaling may inhibit T helper 17 (T_H17) cell differentiation, an effector T cell type implicated in NMO pathogenesis.^{e9} Recent clinical studies also suggest that administration of a monoclonal antibody targeting the IL-6 receptor (tocilizumab) may have clinical benefits in NMO.^{e10,e11} Indeed, the depletion of proinflammatory IL-6-secreting B cells may underpin the therapeutic benefit of rituximab, as plasmablasts and plasma cells do not display CD20 and NMO-IgG titers are generally uninfluenced by rituximab therapy.^{e12,e13} Future focused analyses of B cell subsets (surface biomarkers, idiotype, and affinity maturation) will be necessary to identify and validate a prognostic or therapeutic B cell biomarker in NMO.

III. CYTOKINES, CHEMOKINES, AND OTHER MOLECULAR MARKERS OF INFLAMMATION Circulating soluble mediators as well as B and T cell subsets, cells

of myeloid lineage, and deposition of immunoglobulin (IgG and IgM) complement present in the target organ suggest the participation of multiple cell types in the pathogenesis of NMO.^{29,30} However, the timing and contribution of each player remain to be determined as we learn more about the pathogenesis of NMO. On the one hand, presence of autoantibodies, high levels of serum IL-5 and CCL24 (eotaxin-2), CCL26 (eotaxin-3) in the CSF, B-cell activating factor (BAFF) in serum and CSF, and infiltration of granulocytes suggest involvement of a T_H2 cellular immune response in NMO/NMOSD.^{e14,e15} In addition, there appears to be enhanced expression of T_H17-related (e.g., as IL-17A, IL-6) and T_H1-related (e.g., interferon [IFN]- γ) cytokines in some NMO/NMOSD cohorts.^{e16,e17} Increased levels of additional inflammatory mediators, including IL-1 receptor antagonist, IL-6, CCL8 (IL-8), IL-13, granulocyte colony-stimulating factor (G-CSF), High Mobility Group Box 1 Protein, CXCL13 (BLC), CXCL10 (IP-10), and IL-13-responsive chitinase, have also been detected in the serum or CSF of patients with NMO.^{e18,e19} In addition, cytokine and chemokine profile differences between NMO/NMOSD and MS have been examined and may prove useful as future diagnostic biomarkers.^{e20-e22} Despite the differential expression of these inflammatory markers in the serum of patients with NMO, these markers are also observed in other systemic and inflammatory conditions; thus, the specificity and utility of these biomarkers in NMO remain to be investigated further.

IV. MARKERS OF BBB BREAKDOWN Circulating AQP4-IgG may enter the CNS via the disrupted BBB^{28,30} or may be generated intrathecally.^{e7} Regardless, factors indicative of BBB integrity may serve as surrogate markers of NMO disease activity. One candidate is matrix metalloproteinase-9 (MMP-9), which participates in degradation of collagen IV and is a major component of cerebral vascular endothelial basement membrane.^{e23-e25} Higher serum levels of MMP-9 were reported in patients with NMO compared with patients with MS in a Japanese cohort, and MMP-9 may increase BBB permeability in NMO via an autocrine effect on CNS microvascular endothelial cells.^{e26} A second NMO marker of BBB breakdown, vascular endothelial growth factor-A (VEGF-A), counterregulates claudin-5 and occludin at vascular tight junctions. VEGF-A has been implicated in promoting BBB breakdown in demyelinating disorders.^{e27-e31} A Japanese study found that patients with MS displayed higher serum VEGF-A levels than healthy controls during an acute relapse, with the highest levels in individuals with

opticospinal lesions. Of interest, sera from relapsing patients with NMO induced permeability in an in vitro BBB model, which was reversed by application of an anti-VEGF-A- blocking antibody, suggesting the potential role of VEGF-A in NMO pathology.^{e32} This effect was higher in sera from AQP4-IgG-seronegative patients with NMOSD than seropositive patients, implying factor(s) other than AQP4-IgG regulate BBB perturbation in NMO.

Other BBB-regulating factors include adhesion molecules, notably intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), which also play important roles in lymphocyte migration into the CNS.^{e33-e35} Higher CSF levels of soluble ICAM-1 and soluble VCAM-1 have been reported in patients with relapsing NMO compared with patients with MS or healthy controls and correlate with CSF albumin quotient.^{e36} Collectively, markers of BBB breakdown present another avenue of potential biomarkers in NMO/NMOSD, and future studies are warranted to establish their sensitivity/specificity.

V. T_H LYMPHOCYTE RESPONSE IN NMO Another body of emerging evidence points to critical roles for T lymphocyte subsets in the pathogenesis of NMO/NMOSD. There appears to be a direct relationship between T activation, expansion, and enhanced expression of T_H1, T_H17 cytokines, and AQP4-specific T cells.^{e37} Furthermore, presence of AQP4-specific T cells has been observed.^{e38,e39} IFN- γ -producing T cells were overrepresented compared with IL-4-expressing lymphocytes in the peripheral blood mononuclear cells in patients with OSMS during relapse.^{e40,e41} Elevated IL-17 (from T_H17 cells) and CXCL8 levels in CSF were also observed in patients with OSMS and correlated with extent of spinal cord lesions in NMO.^{e42} IL-17, IFN- γ , and GCSF levels were elevated in the CSF of patients with OSMS regardless of their AQP4-IgG serostatus.^{e43} Recent findings also suggest that CD4⁺: CD8⁺ T cell ratios may be of interest in understanding NMO/NMOSD pathogenesis and therapeutic efficacy, as shown by reduction in ratio following rituximab therapy during NMO relapse.^{e44} Moreover, regulatory T cell expansion also correlated with NMO remission following anti-CD20 therapy.^{e45} However, a comprehensive analysis of the expression, function, and fate of T cell subsets and their corresponding inflammatory mediators in NMO remains to be conducted.

VI. CNS PROTEINS AS BIOMARKERS CNS proteins are detected in sera and CSF of patients with NMO/NMOSD, likely as part of compromised BBB and tissue damage. Neurofilament (NF) heavy-chain levels have been implicated in

inflammatory optic neuropathies in NMO/NMOSD, with high serum NF levels correlating with poor clinical outcome.^{e46} In addition, GFAP and S100B are astrocytic markers detected in the CSF in several inflammatory CNS disorders, including NMO, and are both elevated in AQP4-IgG-seropositive patients.^{e47-e49} CSF and serum levels of S100B correlated with active NMO disease, suggesting that S100B may be a potential biomarker of acute relapse in seropositive NMO. IL-6 and GFAP may also correlate with onset of NMO attack.^{e50} Other studies have suggested that CSF haptoglobin levels may be a biomarker candidate for diagnosis or disease severity in NMO.^{e51}

VII. GENETIC BIOMARKERS To date, as in most autoimmune conditions, there is no direct relationship between any individual gene or gene locus and NMO/NMOSD, suggesting multifactorial etiology with interplay from environmental triggers. Genetic susceptibility loci include HLA-DPB1,^{e52} HLA-DRB1*03:01,^{e53,e54} PD-1.3A allele of *PTPN22*,^{e55} and CD226 Gly307Ser.^{e56} *CYP7A1* gene G/G genotype compared with T/G genotype may have a protective gene dose-dependent effect on the risk of NMO.^{e57} It is interesting that the HLA-DRB1*1501 allele, which is associated with MS, does not appear to be associated with NMO.^{e58} Also, no common single nucleotide polymorphism in *AQP4* appears to be associated with NMO.^{e59} Hence, although all of the above examples offer reasonable insights, additional studies in larger cohorts are necessary to explore potential genetic contributions to NMO/NMOSD.

VIII. COMPOSITE BIOMARKER EVALUATION Beyond assessment of individual biomarkers, it may be useful to explore composite biomarkers and/or biomarker signatures in a complex disease such as NMO/NMOSD. Pattern analysis applied to proteomic data from NMO/NMOSD and MS has suggested composite signatures that differentiate these diseases, especially during relapse.^{e60} Similarly, mass spectrometry and proteome network analyses have been used to generate hypothetical composite biomarkers for potential investigation in NMO/NMOSD,^{e61} MS,^{e62} and systemic lupus erythematosus.^{e63} As with all biomarker discovery or validation efforts, optimal study design is paramount, and any definitive interpretations or conclusions will await prospective masked investigations, preferably among ideally matched and sufficiently large patient cohorts and using optimally standardized methods.

IX. RELATIONSHIP TO CLINICAL DISABILITY Beyond insights into molecular or cellular immunopathology of NMO/NMOSD, further biomarkers are needed to

help predict disease activity and outcomes. Current potential markers include BAFF, a proliferation-inducing ligand, and osteopontin, which correlate with disability in NMO but not MS.^{e15,e64} In addition, CSF levels of CXCL13 (BLC) appear to be elevated in direct proportion to relapse rates and correlate with disability in patients with NMO.^{e22} While more investigation will be necessary to ascertain their clinical relevance, the intersection of biomarkers and disease status represents an important and unmet patient need.

CONCLUSION Sensitive and specific biomarkers are essential for diagnosis, prediction of relapses, prognosis of disease course, and therapeutic response in NMO. If validated, biomarker candidates identified in recent studies will pave the way to a better understanding of NMO pathogenesis. Moreover, they hold promise for greater diagnostic accuracy and individualized care. AQP4-IgG is the best biomarker of NMO to date; however, standardization and optimization of assays are needed. Future investigation into anti-MOG and other non-AQP4 autoantibodies should adjudicate whether these are clinically useful, especially in the context of AQP4-IgG-seronegative cases. Prospective research into T and B lymphocyte immunobiology, cytokine and chemokine profiles, antioxidants, markers of CNS and BBB damage, and genomics/proteomics are expected to accelerate biomarker discovery and validation. In this regard, collaborative longitudinal international biomarker studies with sufficient sample sizes to ensure statistical power should enhance methodologic standardization and promote consistent diagnostic accuracy worldwide. In turn, these advances will support the most informative clinical trials to improve therapies and address unmet needs for patients with NMO and NMOSD. Although beyond the scope of the current review, future efforts should also include delineation of the utility of imaging and post mortem neuropathologic examination in predicting clinical disability in NMO/NMOSD.

AUTHOR CONTRIBUTIONS

Esther Melamed: drafting/revising the manuscript, study supervision. Michael Levy: drafting/revising the manuscript, accepts responsibility for conduct of research and will give final approval. Patrick J. Waters: drafting/revising the manuscript, study concept or design, analysis or interpretation of data. Douglas K. Sato: drafting/revising the manuscript, study concept or design, analysis or interpretation of data. Jeffrey L. Bennett: drafting/revising the manuscript. Gareth R. John: drafting/revising the manuscript. Douglas C. Hooper: drafting/revising the manuscript, study concept or design. Albert Saiz: drafting/revising the manuscript. Amit Bar-Or: drafting/revising the manuscript, study concept or design, analysis or interpretation of data. Ho Jin Kim: drafting/revising the manuscript. Lakha Pandit: drafting/revising the manuscript, study concept or design. Maria Isabel Leite: drafting/revising the manuscript, intellectual contribution. Nasrin Asgari: drafting/revising the manuscript, analysis or interpretation of data. Najib Kissani: drafting/revising the manuscript. Rogier Hintzen: drafting/revising the manuscript.

Romain Marignier: drafting/revising the manuscript. Sven Jarius: drafting/revising the manuscript. John Marcelletti: analysis or interpretation of data, acquisition of data, statistical analysis. Terry J. Smith: drafting/revising the manuscript. Michael R. Yeaman: drafting/revising the manuscript, study concept or design, analysis or interpretation of data, statistical analysis, study supervision. May H. Han: drafting/revising the manuscript, analysis or interpretation of data.

STUDY FUNDING

No targeted funding reported.

DISCLOSURE

E. Melamed reports no disclosures. M. Levy is on the scientific advisory board for Asterias, Chugai, and Alexion; is on the editorial board for *Multiple Sclerosis and Related Disorders*; holds a patent for aquaporin-4 sequence that elicits pathogenic T cell response in animal model of neuromyelitis optica; has consulted for Guidepoint Global, GersonLehrman Group, and Cowen Group; and received research support from Viropharma/Shire, Acorda, ApoPharma, Sanofi, Genzyme, Alnylam, Alexion, Terumo BCT, National Institute of Neurological Disorders and Stroke, and Guthy-Jackson Charitable Foundation. P.J. Waters received speaker honoraria from Biogen Idec Japan and Euroimmun AG; is a review editor for *Frontiers in Molecular Innate Immunity*; holds patents for assays for the detection of antibodies to Igi1, Caspr2, Tag-1, Gabaar; and receives royalty payments for CASPR2, LGI1, TAG-1, GABAAR. D.K. Sato received speaker honoraria from Novartis, is an associate editor for *Arquivos de Neuropsiquiatria*, and received research support from Ministry of Education, Culture, Sports, Science & Technology in Japan, Japanese Government Scholarship Program, Japan Society for the Promotion of Science, and CAPES/Brasil. J.L. Bennett is on the editorial board for *Journal of Neuro-ophthalmology*, *Multiple Sclerosis*, and *Neurology: Neuroimmunology & Neuroinflammation*; holds a patent for compositions and methods for the treatment of neuromyelitis optica; has consulted for EMD-Serono, Questcor Pharmaceuticals, Alnylam Pharmaceuticals, Medimmune, Abbvie, Novartis, Chugai, Genzyme, and Genentech; received research support from Questcor, Novartis, NIH, and Guthy-Jackson Foundation; holds stock in Apsara Therapeutics; and receives license fees and rights for future royalty payments from Aquaporin. G.R. John is on the scientific advisory board for Genzyme and Teva; received travel funding and/or speaker honoraria from National Multiple Sclerosis Society, Guthy-Jackson Charitable Foundation, and Teva; and receives research support from Teva, Genzyme, Novartis, National Institute of Neurological Disorders and Stroke, National Multiple Sclerosis Society, and Guthy-Jackson Charitable Foundation. D.C. Hooper is on the editorial board for *Journal of Immunology Research* and *Scientific Reports*; holds patents for Urate in the treatment of neurodegenerative disease, Human rabies monoclonal antibodies for post-exposure prophylaxis, recombinant rabies vaccines, and reagent for immune modulation; received research support from NIH/NIAID and Albert Stevens Foundation; holds stock in Forest Laboratories; receives license fees from human rabies monoclonal antibodies, Crucell Inc, Rabies vaccines, IDT; and receives royalty payments for human rabies monoclonal antibodies, Crucell Inc/Sanofi-Pasteur. Albert Saiz is on the scientific advisory board for Biogen Idec and Merck-Serono; received travel funding and/or speaker honoraria from Bayer-Schering, Merck-Serono, Biogen, Sanofi-Aventis, Teva, and Novartis; and has consulted for Bayer-Schering, Merck-Serono, Biogen, Sanofi-Aventis, Teva, and Novartis. A. Bar-Or is on the scientific advisory board for Diogenix, Ono Pharmacia, Receptos, Roche, Novartis, GSK, and Guthy-Jackson Greater Good Foundation; is on the editorial board for *Neurology* and *Clinical and Experimental Neuroimmunology*; has consulted for and received travel funding and/or speaker honoraria from Diogenix, Ono Pharmacia, Receptos, Roche, Novartis, and GSK; and received research support from Novartis and Genzyme-Sanofi. H.J. Kim received travel funding and/or speaker honoraria from Bayer-Schering, Biogen, Genzyme, Merck-Serono, Novartis, Teva-Handok, and UCB; is on the editorial board for *Multiple Sclerosis Journal*; and has consulted for Bayer-Schering, Biogen, Genzyme, Medimmune, Merck-Serono, Novartis, Teva-Handok, and UCB. L. Pandit reports no disclosures. M.I. Leite received travel funding and honoraria from Biogen Idec Japan, Novartis, and Genzyme. N. Asgari received research support from The Vejle

Hospital Research Fund of The Region of Southern Denmark and Lundbeck Research Foundation. N. Kissani reports no disclosures. R. Hintzen is on the scientific advisory board for Roche and is a section editor for the journal *Multiple Sclerosis and Related Disorders*. R. Marignier is on the scientific advisory board for Medimmune. S. Jarius reports no disclosures. J. Marcelletti received research support from Tandem Laboratories. T.J. Smith received research support from River Vision, NIH, University of South Denmark, Bell Charitable Foundation, RPB Foundation, and Guthy-Jackson Charitable Foundation. M.R. Yeaman is on the scientific advisory board for Guthy-Jackson Charitable Foundation; is an associate editor for *PLoS Pathogens*; holds patents for vaccines targeting drug-resistant pathogens, immunotherapies targeting drug-resistant pathogens, novel anti-infective biological therapeutics, novel anti-infective small molecules, and novel biological regulating programmed cell death; has consulted for Guthy-Jackson Charitable Foundation; received research support from NovaDigm Therapeutics, Metacin, Inc, United States Department of Defense, and NIH; holds stock in NovaDigm Therapeutics Inc and Metacin, Inc; receives license fee/royalty payments for vaccines targeting drug-resistant pathogens, NovaDigm Therapeutics Inc; and holds stock in NovaDigm Therapeutics Inc. M.H. Han receives research support from Guthy-Jackson Charitable Foundation. Go to Neurology.org/nn for full disclosure forms.

Received February 1, 2015. Accepted in final form June 1, 2015.

REFERENCES

- Devic E. Myélite subaiguë compliquée de névrite optique. *Bull Med* 1984;8:1033–1034.
- Jarius S, Wildemann B. The history of neuromyelitis optica. *J Neuroinflammation* 2013;10:8.
- Beck G. A case of diffuse myelitis associated with optic neuritis. *Brain* 1927;50:687–703.
- Popescu BF, Lennon VA, Parisi JE, et al. Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. *Neurology* 2011;76:1229–1237.
- Collongues N, Cabre P, Marignier R, et al. A benign form of neuromyelitis optica: does it exist? *Arch Neurol* 2011;68:918–924.
- Jiao Y, Fryer JP, Lennon VA, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. *Neurology* 2013;81:1197–1204.
- Bizzoco E, Lolli F, Repice AM, et al. Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. *J Neurol* 2009;256:1891–1898.
- Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. *J Exp Med* 2005;202:473–477.
- Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. *Lancet* 2004;364:2106–2112.
- Magana SM, Pittock SJ, Lennon VA, Keegan BM, Weinshenker BG, Lucchinetti CF. Neuromyelitis optica IgG serostatus in fulminant central nervous system inflammatory demyelinating disease. *Arch Neurol* 2009;66:964–966.
- Wingerchuk DM. Evidence for humoral autoimmunity in neuromyelitis optica. *Neurol Res* 2006;28:348–353.
- Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. *Mult Scler* 2008;14:1157–1174.
- Weinshenker BG, Wingerchuk DM, Vukusic S, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. *Ann Neurol* 2006;59:566–569.
- Takahashi T, Fujihara K, Nakashima I, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titers. *Brain* 2007;130:1235–1243.
- Matiello M, Lennon VA, Jacob A, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. *Neurology* 2008;70:2197–2200.
- Bai S, Liu S, Guo X, et al. Proteome analysis of biomarkers in the cerebrospinal fluid of neuromyelitis optica patients. *Mol Vis* 2009;15:1638–1648.
- Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. *Proc Natl Acad Sci USA* 2011;108:3701–3706.
- Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. *Neurology* 2006;66:1485–1489.
- Jung JS, Preston GM, Smith BL, Guggino WB, Agre P. Molecular structure of the water channel through aquaporin CHIP. The hourglass model. *J Biol Chem* 1994;269:14648–14654.
- Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. *Arch Neurol* 2006;63:964–968.
- Costa C, Tortosa R, Domenech A, Vidal E, Pumarola M, Bassols A. Mapping of aggrecan, hyaluronic acid, heparan sulphate proteoglycans and aquaporin 4 in the central nervous system of the mouse. *J Chem Neuroanat* 2007;33:111–123.
- Saadoun S, Papadopoulos MC. Role of membrane complement regulators in neuromyelitis optica. *Mult Scler Epub* 2015 Feb 19. pii: 1352458515571446.
- Bennett JL, Lam C, Kalluri SR, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. *Ann Neurol* 2009;66:617–629.
- Saadoun S, Papadopoulos MC. Aquaporin-4 in brain and spinal cord oedema. *Neuroscience* 2010;168:1036–1046.
- Zhang H, Verkman AS. Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica. *J Clin Invest* 2013;123:2306–2316.
- Ratelade J, Asavapanumas N, Ritchie AM, Wemlinger S, Bennett JL, Verkman AS. Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica. *Acta Neuropathol* 2013;126:699–709.
- Quan C, Yu H, Qiao J, et al. Impaired regulatory function and enhanced intrathecal activation of B cells in neuromyelitis optica: distinct from multiple sclerosis. *Mult Scler* 2013;19:289–298.
- Lucchinetti CF, Mandler RN, McGovern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. *Brain* 2002;125:1450–1461.
- Misu T, Fujihara K, Kakita A, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. *Brain* 2007;130:1224–1234.
- Roemer SF, Parisi JE, Lennon VA, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. *Brain* 2007;130:1194–1205.
- Hinson SR, Pittock SJ, Lucchinetti CF, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. *Neurology* 2007;69:2221–2231.
- Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. *Neurology* 2012;78:665–671; discussion 669.

33. Apiwattanakul M, Asawavichienjinda T, Pulkes T, et al. Diagnostic utility of NMO/AQP4-IgG in evaluating CNS inflammatory disease in Thai patients. *J Neurol Sci* 2012; 320:118–120.
34. Jarius S, Frederikson J, Waters P, et al. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. *J Neurol Sci* 2010;298:158–162.
35. Höftberger R, Sabater L, Marignier R, et al. An optimized immunohistochemistry technique improves NMO-IgG detection: study comparison with cell-based assays. *PLoS One* 2013;8:e79083.
36. Marignier R, Bernard-Valnet R, Giraudon P, et al. Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. *Neurology* 2013; 80:2194–2200.
37. Fryer JP, Lennon VA, Pittock SJ, et al. AQP4 autoantibody assay performance in clinical laboratory service. *Neurol Neuroimmunol Neuroinflamm* 2014;1:e11. doi: 10.1212/NXI.000000000000011.
38. Pittock SJ, Lennon VA, Bakshi N, et al. Seroprevalence of aquaporin-4-IgG in a northern California population representative cohort of multiple sclerosis. *JAMA Neurol* 2014;71:1433–1436.
39. Ketelslegers IA, Modderman PW, Vennegoor A, Killestein J, Hamann D, Hintzen RQ. Antibodies against aquaporin-4 in neuromyelitis optica: distinction between recurrent and monophasic patients. *Mult Scler* 2011;17:1527–1530.
40. Nishiyama S, Ito T, Misu T, et al. A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset. *Neurology* 2009;72:1960–1961.
41. Watanabe S, Nakashima I, Misu T, et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. *Mult Scler* 2007;13: 128–132.
42. Bonnan M, Valentino R, Olindo S, Mehdaoui H, Smadja D, Cabre P. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. *Mult Scler* 2009;15:487–492.
43. Adoni T, Lino AM, da Gama PD, et al. Recurrent neuromyelitis optica in Brazilian patients: clinical, immunological, and neuroimaging characteristics. *Mult Scler* 2010; 16:81–86.
44. Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. *Brain* 2008;131:3072–3080.
45. Nakashima I, Fujihara K, Miyazawa I, et al. Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. *J Neurol Neurosurg Psychiatry* 2006;77:1073–1075.
46. Paul F, Jarius S, Aktas O, et al. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. *PLoS Med* 2007;4: e133.
47. Jarius S, Franciotta D, Bergamaschi R, et al. NMO-IgG in the diagnosis of neuromyelitis optica. *Neurology* 2007;68: 1076–1077.
48. Fazio R, Malosio ML, Lampasona V, et al. Anti-aquaporin 4 antibodies detection by different techniques in neuromyelitis optica patients. *Mult Scler* 2009;15:1153–1163.
49. Tanaka M, Tanaka K, Komori M, Saida T. Anti-aquaporin 4 antibody in Japanese multiple sclerosis: the presence of optic spinal multiple sclerosis without long spinal cord lesions and anti-aquaporin 4 antibody. *J Neurol Neurosurg Psychiatry* 2007;78:990–992.
50. Yang Y, Huang DH, Wu WP, Wu L, Chen LF, Wu Q. The role of aquaporin-4 antibodies in Chinese patients with neuromyelitis optica. *J Clin Neurosci* 2013;20:94–98.
51. Cabrera-Gomez JA, Kurtzke JF, Gonzalez-Quevedo A, Lara-Rodriguez R. An epidemiological study of neuromyelitis optica in Cuba. *J Neurol* 2009;256:35–44.
52. Waters P, Reindl M, Schanda K, et al. Assessment of aquaporin-4 (AQP4) antibody assays in European diagnostic centres. *J Neuroimmunol* 2014;275:15.
53. Rostásy K, Mader S, Schanda K, et al. Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. *Arch Neurol* 2012;69:752–756.
54. McLaughlin KA, Chitnis T, Newcombe J, et al. Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. *J Immunol* 2009;183: 4067–4076.
55. Rostásy K, Mader S, Hennes EM, et al. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. *Mult Scler* 2013;19:1052–1059.
56. Brunner C, Lassmann H, Waehnelndt TV, Matthieu JM, Linington C. Differential ultrastructural localization of myelin basic protein, myelin/oligodendroglial glycoprotein, and 2',3'-cyclic nucleotide 3'-phosphodiesterase in the CNS of adult rats. *J Neurochem* 1989;52:296–304.
57. Mader S, Gredler V, Schanda K, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. *J Neuroinflammation* 2011;8:184.
58. Ramanathan S, Reddel SW, Henderson A, et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. *Neurol Neuroimmunol Neuroinflamm* 2014;1:e40. doi: 10.1212/NXI.0000000000000040.
59. Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. *JAMA Neurol* 2014;71:276–283.
60. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. *Neurology* 2014;82:474–481.